In May of this year, the National Health and Family Planning Committee held a remediation meeting, and immune cell therapy was required to stop being applied to clinical treatment. This gave the immune cell treatment enterprises that are still expecting the outbreak of the industry to “be a good startâ€, and the cell therapy industry in China has also entered a cold winter. In a medical research institution, researchers are conducting experiments on cell therapy. How can the cell therapy industry achieve “self-rescue†when national policies are still unclear? On September 11, the Shenzhen Cell Therapy Technology Association (hereinafter referred to as the “Associationâ€), initiated by Shenzhen University, Shenzhen Luohu Hospital, Shenzhen Research Institute of Tsinghua University and Shenzhen Heyi Kang Bio, was formally established. Home cell therapy companies and universities, research institutions, hospitals "bringing groups to warm up." After the establishment of the association, the development of industry standards, practitioners' technical training, public service platform construction, clinical research, etc. will be promoted to promote the development of cell therapy, research, research and medicine in Shenzhen. It is reported that the association is also the first industry organization in the field of cell therapy in Shenzhen. The association plans to introduce the local standard for cell therapy technology in Shenzhen in the first half of 2017. Immune cell therapy companies have seen a sharp drop in revenue this year In the past 10 years, China's cell therapy technology has developed by leaps and bounds, and the cell therapy industry in Shenzhen has also been at the forefront of the country. Liu Wei, deputy dean of Shenzhen Zhongxun Precision Medicine Research Institute and secretary general of Shenzhen Cell Therapy Technology Association, said that in recent years, the cell therapy industry in Shenzhen has taken shape, and the main business of cell therapy is more than 40, Shenzhen City. Class III A hospitals have the ability to treat different cell types. At the same time, Shenzhen City has been approved two "cellulant team" related to cell therapy. The city has more than 200 invention patents in cell-related countries, and the industry has attracted more than 100 high-level overseas students. However, due to the rapid development of cell therapy technology and the rapid development of national regulatory policies, the industry has developed various problems in recent years, especially the “Weize Zexi incident†in May this year, which led the country to quickly stop cell therapy. The income of the company, which is the main business, also fell sharply. Recently, the first report of the immune cell treatment listed on the New Third Board last year, Shenzhen Heyikang’s mid-year report showed that the income from January to June this year was 17.46 million yuan, down 30.05% year-on-year. The net profit attributable to shareholders of the parent company was - 11.95 million yuan, a sharp drop of 544.03%. BTE Hearing Aid BTE Hearing Aid Shenzhen Sunshine Technology Co.,Ltd , https://www.szyatwin.com